A DEA officer stops at a ranch in Texas, and talks with an old rancher. He tells the rancher, “I need to inspect your ranch for illegally grown drugs.” The rancher says, “Okay, but do not go in that field over there,” as he points out the location. The DEA officer verbally explodes saying, “Mister, I have the authority of the Federal Government with me.” Reaching into his rear pants pocket, he removes his badge and proudly displays it to the rancher. “See this badge? This badge means I am allowed to go wherever I wish, on any land. No questions asked or answers given. Have I made myself clear? Do you understand?”
The rancher nods politely, apologizes, and goes about his chores.
A short time later, the old rancher hears loud screams and sees the DEA officer running for his life chased by the rancher’s big Santa Gertrudis bull! With every step the bull is gaining ground on the officer, and it seems likely that he’ll get gored before he reaches safety. The officer is clearly terrified. The rancher throws down his tools, runs to the fence and yells at the top of his lungs… “Your badge. Show him your BADGE!”
Under (market) pressure
Most companies, even those in the commodity space, that are well managed can weather the ups and downs of commodity prices without having to make cuts to their payouts. Typically, those well-run companies were conservative enough in paying shareholders that there was a cushion to pad any fall in prices. For the past several years, Alliance Resource Partners fit that bill. Despite being in the coal business -- not exactly a growing industry -- the company had managed to remain solidly profitable with its low-cost mines by taking market share from others and not taking on too much debt. Even today, the company has a pretty clean balance sheet in an industry that has become morbidly bloated on debt.
Unfortunately for Alliance, there are external factors that continue to weigh on the coal market. Cheap natural gas continues to take market share in the electricity market, and exports of coal to places such as China haven't been what companies had expected them to be just a couple of years ago. This has led to a huge buildup of coal stocks to the point that prices for new coal production are at or below every player's ability to make money.
The company already decided that in 2016 it would keep its payout the same as last year's, halting a 12-year streak of constant increases. Still, with coal inventories continuing to build up and bankrupt producers still sending coal to market, things are looking like they will keep getting worse to the point that Alliance's payout may not be sustainable for much longer.
I wish I could say I got in at $24.50 like planed . But I broke weak at @.$25.25 a share on April fools day I should have waited another week or two . As long as I'm wishing , I wish I had more money to add shares at $24,50 or below . I like CSX because it raises it's dividend and it will do well as the economy gets better .
Well best of luck to all .
I really don't care if I never make it into the top 5%. I'm just happy to invest my money . Then spend the dividends . I don't need to make a killing . I'm just happy to keep what I have and spend the interest . As you can see by my earlier post , I won't be here 9 months from now . As I already sold my shares on 12/4/15 at a lost . That's not to say I don't hope you're still making money 9 months from now . As a matter of fact , I wish you all the best of luck with ARLP.
wareham2620 wareham2620 • Jan 26, 2016 11:19 AM
I still think ARLP is the only coal stock to take a chance on . However, I got out at a lost of my purchase price .That is after many years of great returns on my investment with ARLP .The reason I got out was the meeting in Paris and ARLP's earnings heading down .
Then the railroad article I've read " after I sold ARLP " stated ,their drop in all shipments. Coal led the decline with a 32 percent drop in carloads . Then you ask why am I here ? Well I just keep looking back to see if I should kick myself in the a$$ or not .
According to yahoo the earning per share are heading down . TTM $3.47
this year $3.07 and next year $2.54
Jan. 13, 2016,MAHA, Neb. (AP) — CSX Corp. expects to deliver lower profits in 2016 as weak demand for coal and crude oil persists and the strong U.S. dollar continues to limit exports.
The railroad's forecast for lower freight volume suggests the overall U.S. economy may be slowing after several years of steady growth.
"We're calling it almost a freight recession," Chairman and CEO Michael Ward said Wednesday. "We really think there are some challenges on the industrial side of the economy."
The railroad's fourth-quarter results showed an overall 6 percent drop in all shipments. Coal led the decline with a 32 percent drop in carloads, but few sectors showed any growth.
Ward said the railroad will continue working to improve productivity and cut about $200 million in expenses in 2016.
CSX also plans to reduce its capital spending this year by $100 million to $2.4 billion and park some older, less-efficient locomotives that aren't needed.
"2016 will be a more challenging year," Ward said. "Volume in the first quarter and for the full year will decline as growth in some markets continues to be offset by the significant impact of continued coal declines, low commodity prices and a strong US dollar."
Coal demand has fallen significantly over the past several years because of environmental concerns and because cheap natural gas prices prompted some utilities to switch fuels.
Intermodal shipments of containers that arrive in ports via ship grew 4 percent for one of the only major bright spots in CSX's traffic report. Automotive shipments improved 5 percent in the quarter.
The Jacksonville, Florida-based railroad said Tuesday its fourth-quarter profit declined 5 percent to $466 million, or 48 cents per share, on $2.78 billion revenue.
The quarterly results were helped by a one-time property sale that added $80 million, or 5 cents per share, to CSX's profit. Analysts surveyed by Zacks Investment Research expected adjusted earnings of 46 cents per share.
Citi analyst Christian Wetherbee said the railroad's results were better than he expected thanks to tight cost controls.
CSX operates more than 21,000 miles of track in 23 Eastern states and two Canadian provinces.
Its shares fell $1.67, or 7.1 percent, to $22.03 in afternoon trading Wednesday. Its shares are down more than 34 percent over the past year.
I'm about 85% in the hole on my investment with CLMT . They have stopped the distribution . But
I'm thinking about buying more here . I do my own investing so I'm not taking to a broker . My shrink is out of town . That means I'm on my own here . However, to my way of thinking this stock should have been doing great while the oil was low . But , that didn't happen . Now, I'm thinking when / or if they return our distributions this stock will jump . The question is will they return our distributions ? Also , when ? Then on the other hand , is CLMT just history at this point ? The voices in my head say , at this price it's not much of a risk anyway .
Doubling down at $3.60 wasn't s a mistake . As you're making money so far . I don't do my own taxes . But selling your original investment at a loss for taxes reasons , I've heard of that before.
According to yahoo the TTM earnings was -$3.14 , this years estimated at - $1.64 , and next years is estimated at -0.30 . So to me , it looks to be coming back in time .Maybe by 2018 we will be back in the green . CLMT looks like it may be high risk . But at this price it's under book . I just hope the new CEO can turn things around again .
Well best of luck to you .
Insider Transactions Reported - Last Two Years
Feb 8, 2016 CONLEE CECIL D
3,000 Direct Option Exercise at $0.01 - $0.01 per share. 302
Feb 8, 2016 HATHORN SAMUEL C
18,000 Direct Option Exercise at $1.22 - $1.22 per share. 22,0002
Feb 8, 2016 BRACKEN GEORGE R
4,800 Direct Option Exercise at $1.25 - $1.25 per share. 6,0002
Jan 19, 2016 CAPORELLA JOSEPH G
42,000 Direct Option Exercise at $1.75 - $1.75 per share. 74,0002
Nov 12, 2015 COOK GREGORY P
2,400 Direct Option Exercise at $6.21 - $6.21 per share. 15,0002
Sep 23, 2015 CONLEE CECIL D
1,600 Direct Purchase at $28.38 - $28.38 per share. 45,0002
Dec 17, 2014 CAPORELLA JOSEPH G
2,200 Direct Option Exercise at $0.01 - $0.01 per share. 222
Aug 25, 2014 THOMPSON DENNIS L
3,000 Direct Statement of Ownership N/A
Aug 12, 2014 HATHORN SAMUEL C
3,000 Direct Acquisition (Non Open Market) at $0.01 - $0.01 per share. 302
Aug 1, 2014 BRACKEN GEORGE R
120,000 Indirect Disposition (Non Open Market) at $50 - $50 per share. 6,000,0002
Jul 15, 2014 COOK GREGORY P
8,984 Direct Statement of Ownership N/A
Data provided by EDGAR Online
* = Where indicated, some values are estimates.
I thought GSK would have jumped on this news .But going down now
11:43 am GlaxoSmithKline: European Commission approves GSK's Strimvelis (GSK) :
•Co announces that the European Commission has approved Strimvelis, the first ex-vivo stem cell gene therapy to treat patients with a very rare disease called ADA-SCID.
•Strimvelis is the first corrective gene therapy for children to be awarded regulatory approval anywhere in the world.
•It is indicated for the treatment of patients with ADA-SCID for whom no suitable human leukocyte antigen matched related stem cell donor is available.
Adenosine deaminase (ADA) deficiency is an inherited disorder that damages the immune system and causes severe combined immunodeficiency (SCID). People with SCID lack virtually all immune protection from bacteria, viruses, and fungi. They are prone to repeated and persistent infections that can be very serious or life-threatening. These infections are often caused by "opportunistic" organisms that ordinarily do not cause illness in people with a normal immune system.
The main symptoms of ADA deficiency are pneumonia, chronic diarrhea, and widespread skin rashes. Affected children also grow much more slowly than healthy children and some have developmental delay.
Most individuals with ADA deficiency are diagnosed with SCID in the first 6 months of life. Without treatment, these babies usually do not survive past age 2. In about 10 percent to 15 percent of cases, onset of immune deficiency is delayed to between 6 and 24 months of age (delayed onset) or even until adulthood (late onset). Immune deficiency in these later-onset cases tends to be less severe, causing primarily recurrent upper respiratory and ear infections. Over time, affected individuals may develop chronic lung damage, malnutrition, and other health problems.
The Insider Transactions Reported - Last Two Years have all been buys and none sold .The earnings per share has been heading up according to Yahoo. TTM 0.91 , this years expected earnings 0.99 and next years expected earnings of 1.18 , so things are looking good from here .
JACKSONVILLE, Fla., May 13, 2016 (GLOBE NEWSWIRE) -- On Wednesday, the Board of Directors of CSX Corporation (CSX) approved an $0.18 per share quarterly dividend on the company's common stock. The dividend is payable on June 15, 2016, to shareholders of record at the close of business on May 31, 2016.
Yes , one he!! of a buying opportunity. That's why I'm looking at this stock now . Looking for that buying opportunity.
Best of luck to you .
I've also had CLMT for years now . My higher price was @ $27.90 . I'm not a trader , just an investor . I only buy stocks for their dividends and or distributions . However , I added another 90 shares at $4.50 per share , I'm hoping that they return the dividend by 2018 , Also , hoping to see the stock price going back up while I'm waiting . I've recently bought GSK , CSX and PFE . Therefore , I didn't have as much cash as I thought . Or I would have bought more here .
Yahoo shows book just over $6.
Well best of luck to you .
•GSK lung drug succeeds in big UK study, after earlier miss
NASDAQMon, May 23, 2016
LONDON, May 24 (Reuters) - GlaxoSmithKline's new inhaled medicine Breo proved significantly better than standard care in a large British study that tested it in everyday use, providing a fillip for the product after the failure of another big trial in 2015.
GSK said on Tuesday that the study, which tested Breo in day-to-day practice across the town of Salford, showed it was superior in reducing attacks of serious breathing difficulties in patients with chronic obstructive pulmonary disease (COPD).
There was a statistically significant reduction of 8.4 percent in the rate of moderate or severe exacerbations compared with those receiving usual care, the study found.
The success comes after another more traditional clinical trial in September found Breo failed to prolong life in COPD patients.
Britain's largest drugmaker is relying on Breo, which was approved in 2013, to help defend its respiratory drug business as its older blockbuster Advair faces generic competition. U.S. drugmaker Innoviva is GSK's partner for Breo.
As you stated , "you have seen this story before ." So have I . I just copied and pasted to point out a few things .
What differentiates this commodity?.....A great taste that the people like.
A well designed bottle? .... That's just part of good salesmanship .
It matters not how they got the people to try this drink . But the fact that the people tried it and liked it enough to continue drinking it . Hopefully , they will offer their guest one and the growth continues .
The fact FIZZ found a good drink and could get the consumers to try it ......... I'm in FIZZ @ $13.92 a share and not willing to sell it all now . I think it's a hold and see if the growth continues . I'm betting it will , as this Company is making money.
Well best of luck to you .
Well according to yahoo CLMT shows TTM earnings at -$3.14 , this years estimated at - $1.64 , and next years is estimated at -0.30 . So to me , it looks to be coming back in time . Then on the other hand , I bought IEP @ $102.70 a share because I was looking at yahoo's estimated earnings . Those estimated earnings where changed shortly after I bought IEP . Now IEP is about $57. per share , but still paying a $6.00 dividend . I was going to use Google rather than Yahoo . But I didn't want them to have my phone number .
I recently bought GSK , CSX and PFE . Therefore , I didn't have as much money as I thought . However, I was able to add another 90 shares of CLMT anyway .
Well thanks and best of luck to you .
I remember thinking the same thing not to long ago . As for myself , I just bought some of each . However, I bought at a higher price . But hell , I'm still happy . With so many family and friends living in these places .Then getting out only to return again and again . Well , why should I bet against them . This way crime pays them or it pays me . Either way, crime has been putting money in my families pocket for sometime now .
Now on the other hand , GEO has a better return . So if I was to pick just one it would be GEO .
Also, check out FUN and it's dividend history . T , VZ ,GM and F looks OK , but with a lower returns for your investment .
Well best of luck to you .